Annual CFO
-$155.50 M
-$39.14 M-33.64%
December 31, 2024
Summary
- As of March 10, 2025, PLRX annual cash flow from operations is -$155.50 million, with the most recent change of -$39.14 million (-33.64%) on December 31, 2024.
- During the last 3 years, PLRX annual CFO has fallen by -$80.06 million (-106.12%).
- PLRX annual CFO is now -5554.65% below its all-time high of -$2.75 million, reached on December 31, 2019.
Performance
PLRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$47.66 M
-$15.39 M-47.68%
December 31, 2024
Summary
- As of March 10, 2025, PLRX quarterly cash flow from operations is -$47.66 million, with the most recent change of -$15.39 million (-47.68%) on December 31, 2024.
- Over the past year, PLRX quarterly CFO has stayed the same.
- PLRX quarterly CFO is now -229.71% below its all-time high of $36.74 million, reached on December 31, 2019.
Performance
PLRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$155.50 M
-$22.56 M-16.97%
December 31, 2024
Summary
- As of March 10, 2025, PLRX TTM cash flow from operations is -$155.50 million, with the most recent change of -$22.56 million (-16.97%) on December 31, 2024.
- Over the past year, PLRX TTM CFO has stayed the same.
- PLRX TTM CFO is now -1021.55% below its all-time high of $16.87 million, reached on June 30, 2020.
Performance
PLRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
PLRX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.6% | 0.0% | 0.0% |
| 3 y3 years | -106.1% | 0.0% | 0.0% |
| 5 y5 years | -5554.6% | 0.0% | 0.0% |
PLRX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -106.1% | at low | -157.7% | at low | -106.1% | at low |
| 5 y | 5-year | -5554.6% | at low | -229.7% | at low | -1021.5% | at low |
| alltime | all time | -5554.6% | at low | -229.7% | at low | -1021.5% | at low |
Pliant Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$155.50 M(+33.6%) | -$47.66 M(+47.7%) | -$155.50 M(+17.0%) |
| Sep 2024 | - | -$32.27 M(-28.8%) | -$132.94 M(-2.9%) |
| Jun 2024 | - | -$45.30 M(+49.6%) | -$136.89 M(+17.7%) |
| Mar 2024 | - | -$30.27 M(+20.6%) | -$116.36 M(-0.0%) |
| Dec 2023 | -$116.36 M(+23.0%) | -$25.10 M(-30.7%) | -$116.36 M(-5.0%) |
| Sep 2023 | - | -$36.22 M(+46.3%) | -$122.50 M(+16.9%) |
| Jun 2023 | - | -$24.76 M(-18.2%) | -$104.77 M(+0.3%) |
| Mar 2023 | - | -$30.28 M(-3.1%) | -$104.41 M(+10.3%) |
| Dec 2022 | -$94.63 M(+25.4%) | -$31.24 M(+68.9%) | -$94.63 M(+13.7%) |
| Sep 2022 | - | -$18.50 M(-24.2%) | -$83.26 M(-4.6%) |
| Jun 2022 | - | -$24.40 M(+19.0%) | -$87.27 M(+6.1%) |
| Mar 2022 | - | -$20.50 M(+3.2%) | -$82.28 M(+9.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$75.44 M(+102.4%) | -$19.86 M(-11.8%) | -$75.44 M(+4.7%) |
| Sep 2021 | - | -$22.51 M(+16.0%) | -$72.06 M(+10.3%) |
| Jun 2021 | - | -$19.40 M(+42.0%) | -$65.34 M(+71.2%) |
| Mar 2021 | - | -$13.66 M(-17.1%) | -$38.17 M(+2.4%) |
| Dec 2020 | -$37.27 M(+1255.3%) | -$16.48 M(+4.4%) | -$37.27 M(-333.6%) |
| Sep 2020 | - | -$15.79 M(-303.2%) | $15.96 M(-5.4%) |
| Jun 2020 | - | $7.77 M(-160.9%) | $16.87 M(-461.4%) |
| Mar 2020 | - | -$12.77 M(-134.7%) | -$4.67 M(+69.8%) |
| Dec 2019 | -$2.75 M(-90.3%) | $36.74 M(-347.0%) | -$2.75 M(-93.0%) |
| Sep 2019 | - | -$14.88 M(+8.0%) | -$39.49 M(+60.4%) |
| Jun 2019 | - | -$13.77 M(+27.0%) | -$24.62 M(+127.0%) |
| Mar 2019 | - | -$10.85 M | -$10.85 M |
| Dec 2018 | -$28.33 M | - | - |
FAQ
- What is Pliant Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Pliant Therapeutics?
- What is Pliant Therapeutics annual CFO year-on-year change?
- What is Pliant Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Pliant Therapeutics?
- What is Pliant Therapeutics quarterly CFO year-on-year change?
- What is Pliant Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Pliant Therapeutics?
- What is Pliant Therapeutics TTM CFO year-on-year change?
What is Pliant Therapeutics annual cash flow from operations?
The current annual CFO of PLRX is -$155.50 M
What is the all time high annual CFO for Pliant Therapeutics?
Pliant Therapeutics all-time high annual cash flow from operations is -$2.75 M
What is Pliant Therapeutics annual CFO year-on-year change?
Over the past year, PLRX annual cash flow from operations has changed by -$39.14 M (-33.64%)
What is Pliant Therapeutics quarterly cash flow from operations?
The current quarterly CFO of PLRX is -$47.66 M
What is the all time high quarterly CFO for Pliant Therapeutics?
Pliant Therapeutics all-time high quarterly cash flow from operations is $36.74 M
What is Pliant Therapeutics quarterly CFO year-on-year change?
Over the past year, PLRX quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Pliant Therapeutics TTM cash flow from operations?
The current TTM CFO of PLRX is -$155.50 M
What is the all time high TTM CFO for Pliant Therapeutics?
Pliant Therapeutics all-time high TTM cash flow from operations is $16.87 M
What is Pliant Therapeutics TTM CFO year-on-year change?
Over the past year, PLRX TTM cash flow from operations has changed by $0.00 (0.00%)